WNT antagonists may act as tumour suppressors and cause constitutive activation of WNT signalling when mutated; reduced expression of the secreted WNT inhibitors SFRP1 and WIF1 have been observed in breast cancers [71–73]. This evidence concerns the gene WIF1 and neoplasm.